A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
Clinical trial NCT05234684 · UNKNOWN
Trial details
- NCT number
- NCT05234684
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-02
- Primary completion
- 2024-07-30
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.